Charles River Laboratories has been on an acquisition spree. But Tuesday, it offloaded two assets
Following a summer filled with mergers and acquisitions, Charles River Laboratories has divested its research operations in Japan and a CDMO site in Sweden, engineering two separate deals expected to cut down $20 million in revenue.
Tuesday, Charles River sold its gene therapy CDMO site to a private investor group for about $52 million in cash, with the potential for contingent payments up to $25 million. The site was in the company’s possession for only a few months, as it was acquired from Cognate BioServices on March 29.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.